Kobe

The Kobe Pharma Research Institute (KPRI)

Boehringer Ingelheim established its research and development presence in Japan in 1969, with the aim of developing and submitting new human pharmaceuticals. Originally, this R&D site was based in Kawanishi, Kansai region. In 2008, it was transferred to its current location in nearby Kobe, where it is known as the Kobe Pharma Research Institute (KPRI). Today, more than 80 employees work in the areas of Discovery Research (RBB), Development (NCE), and Business Development & Licensing.

Front view of the research building, Kobe

The KPRI participates in the global R&D activities for human pharmaceuticals, and its main tasks constitute scouting innovations and new technologies in Japan. On top of that, the KPRI supports new drug development and also market submission in order to maximize the value of new products for the Japanese market.

Sites Around the World

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany. It is the largest site, producing all new active ingredients and medications during the market launch.

Biberach

The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany. This site is also the largest site in Europe for biopharmaceutical manufacturing.